Rozenblum Laura, Houillier Caroline, Soussain Carole, Bertaux Marc, Choquet Sylvain, Galanaud Damien, Hoang-Xuan Khê, Kas Aurélie
Service de Médecine Nucléaire, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, AP-HP, Sorbonne Université, 75013 Paris, France.
Laboratoire d'Imagerie Biomédicale, INSERM U1146, 75006 Paris, France.
Cancers (Basel). 2022 Aug 23;14(17):4071. doi: 10.3390/cancers14174071.
The incidence of primary central nervous system lymphoma has increased over the past two decades in immunocompetent patients and the prognosis remains poor. A diagnosis and complete evaluation of the patient is needed without delay, but histologic evaluation is not always available and PCNSL can mimic a variety of brain lesions on MRI. In this article, we review the potential role of F-FDG PET for the diagnosis of PCNSL in immunocompetent and immunocompromised patients. Its contribution to systemic assessment at the time of diagnosis has been well established by expert societies over the past decade. In addition, F-FDG provides valuable information for differential diagnosis and outcome prediction. The literature also shows the potential role of F-FDG as a therapeutic evaluation tool during the treatment and the end of the treatment. Finally, we present several new radiotracers that may have a potential role in the management of PCNSL in the future.
在过去二十年中，免疫功能正常患者的原发性中枢神经系统淋巴瘤发病率有所上升，且预后仍然较差。需要立即对患者进行诊断和全面评估，但组织学评估并非总能实现，并且原发性中枢神经系统淋巴瘤在磁共振成像（MRI）上可模仿多种脑病变。在本文中，我们回顾了F-FDG PET在免疫功能正常和免疫功能低下患者原发性中枢神经系统淋巴瘤诊断中的潜在作用。在过去十年中，专家协会已充分证实其在诊断时对全身评估的贡献。此外，F-FDG为鉴别诊断和预后预测提供了有价值的信息。文献还显示了F-FDG作为治疗期间和治疗结束时治疗评估工具的潜在作用。最后，我们介绍了几种可能在未来原发性中枢神经系统淋巴瘤管理中发挥潜在作用的新型放射性示踪剂。
